Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 21 clinical trials
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

This is a multi-center, open-label, phase IIa study to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL. The study consists of two parts. A total of 24-36 T-PLL patients will be enrolled.

  • 24 Jul, 2022
  • 3 locations
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

refractory multiple myeloma
cutaneous t-cell lymphoma
fungal infection
prolymphocytic leukemia
neutrophil count
  • 05 May, 2022
  • 15 locations
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the

  • 12 Jul, 2022
  • 1 location
Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is a study for people who have been previously treated for Leukemia/Lymphoma. In particular, it is a study for people who have a type of Leukemia/Lymphoma that involves B cells (a type of white cell), which contain the cancer. This is a new approach for treatment of Leukemia/Lymphoma that …

tumor cells
  • 07 Nov, 2020
  • 1 location
Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of autologous anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

  • 16 Apr, 2021
  • 1 location
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this …

t-cell lymphoma
cutaneous t-cell lymphoma
peripheral t-cell lymphoma
prolymphocytic leukemia
lymphoid leukemia
  • 03 May, 2022
  • 1 location
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

  • 15 Mar, 2021
  • 1 location
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come back (relapsed) or has not responded to treatment (refractory). Pegcrisantaspase may block the growth of cancer cells. Chemotherapy drugs, such …

  • 11 Mar, 2022
  • 1 location
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Background Some people with cancer have solid tumors. Others have refractory leukemia. This doesn t go away after treatment. Researchers want to see if a drug called PLX3397 can shrink tumors or stop them from growing. Objectives To find the highest safe dose and side effects of PLX3397. To see …

neutrophil count
cancer chemotherapy
ewing's sarcoma
immunosuppressive agents
  • 23 Jul, 2022
  • 1 location
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

). Lymphoid malignancies eligible for this trial are: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-prolymphocytic leukemia (B-PLL). T-cells (a type

  • 27 Jul, 2022
  • 1 location